Pharmacare News Bulletins
Nova Scotia Pharmacare
Pharmacare News Bulletins
The Pharmacare News Bulletins, which are mailed to pharmacies and prescribers, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.
Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.
Pharmacy edition
Latest Issues
September Bulletin Vol 22-13 (PDF)
Non-Insured Product: Zolgensma (onasemnogene abeparvovec); New Exception Status Benefit: Evrysdi (risdiplam); Criteria Updates: Benzydamine, Akynzeo (netupitant/palonosetron), Emend (aprepitant); Change in Benefit Status: Rexulti (brexpiprazole); New Benefit: Xolair (omalizumab) PFS
August Bulletin Vol 22-12 (PDF)
New Exception Status Benefits: Vyndaqel, Vyndamax, Kesimpta, MAR-Trientine, Prometrium and generics, JAMP Prasugrel; Criteria Updates: Lynparza, Pulmicort Nebules, Actemra, PPIs; Change in Benefit Status: Cholinesterase Inhibitors... New Benefit; Temporary Benefit; CF Therapies Update; New Diabetic Product
July Bulletin Vol 22-11 (PDF)
New Exception Status Benefits: Alunbrig (brigatinib), Ilumya (tildrakizumab), Yuflyma (adalimumab), Verkazia (cyclosporine); New Benefits: Skyrizi (risankizumab)
June Bulletin Vol 22-10 (PDF)
New Exception Status Benefits: Crysvita (burosumab), Calquence (acalabrutinib), Mayzent (siponimod), Tegsedi (inotersen), Baqsimi (glucagon), Entuzity (human insulin R); Criteria Update: Forxiga (dapagliflozin), Rituximab Biosimilars, Venclexta (venetoclax)
May Bulletin Vol 22-09 (PDF)
New Exception Status Benefits: Abrilada (adalimumab), Simlandi (adalimumab), Duobrii (halobetasol propionate and tazarotene); Criteria Update: Ofev (nintedanib); Public Funding of Pharmacist Assessment for COVID-19 Therapies; COVID-19 Immunizations
April Bulletin Vol 22-08 (PDF)
New Exception Status Benefits: Zejula (niraparib), Adlyxine (lixisenatide), Entyvio (vedolizumab)
April Bulletin Vol 22-07 (PDF)
Change to Maximum Reimbursable Prices
April Bulletin Vol 22-06 (PDF)
Update on Audit of Patient Consent Documentation, Changes to Naloxone Kit Billing
March Bulletin Vol 22-05 (PDF)
Virtual Care Update; Prescription Renewals for Pharmacy Closures; New Diabetic Products
February Bulletin Vol 22-04 (PDF)
New Exception Status Benefits Ajovy (fremanezumab); Monoferric (ferric derisomaltose); Opsumit (macitentan); Riabni (rituximab). Criteria Updates Androgel and generic brands (testosterone); Testim (testosterone); Zofran and generic brands (ondansetron); Cosentyx (secukinumab)
February Bulletin Vol 22-03 (PDF)
Change in Coverage of Biologics, Expansion of Community Pharmacist-led Anticoagulation Management Services (CPAMS), RN Prescribing
February Bulletin Vol 22-02 (PDF)
New Exception Status Benefit: Nyvepria (pegfilgrastim)
January Bulletin Vol 22-01 (PDF)
COVID-19 Updates to Public Coverage
Prescribers' edition
Latest Issue
September Bulletin Vol 22-08 (PDF)
Non-Insured Product: Zolgensma (onasemnogene abeparvovec); New Exception Status Benefit: Evrysdi (risdiplam); Criteria Updates: Benzydamine, Akynzeo (netupitant/palonosetron), Emend (aprepitant); Change in Benefit Status: Rexulti (brexpiprazole); New Benefit: Xolair (omalizumab) PFS
August Bulletin Vol 22-07 (PDF)
New Exception Status Benefits: Vyndaqel, Vyndamax, Kesimpta, MAR-Trientine, Prometrium and generics, JAMP Prasugrel; Criteria Updates: Lynparza, Pulmicort Nebules, Actemra, PPIs; Change in Benefit Status: Cholinesterase Inhibitors... New Benefit; Temporary Benefit; CF Therapies Update; New Diabetic Product
July Bulletin Vol 22-06 (PDF)
New Exception Status Benefits: Alunbrig (brigatinib), Ilumya (tildrakizumab), Yuflyma (adalimumab), Verkazia (cyclosporine); New Benefits: Skyrizi (risankizumab)
June Bulletin Vol 22-05 (PDF)
New Exception Status Benefits: Crysvita (burosumab), Calquence (acalabrutinib), Mayzent (siponimod), Tegsedi (inotersen), Baqsimi (glucagon), Entuzity (human insulin R); Criteria Update: Forxiga (dapagliflozin), Rituximab Biosimilars, Venclexta (venetoclax); New Diabetic Product; Non-Insured Products; Non-Insulin Antidiabetic Agents
May Bulletin Vol 22-04 (PDF)
New Exception Status Benefits: Abrilada (adalimumab), Simlandi (adalimumab), Duobrii (halobetasol propionate and tazarotene); Criteria Update: Ofev (nintedanib); Budesonide for Patients with Non-severe COVID-19 Respiratory Symptoms
April Bulletin Vol 22-03 (PDF)
New Exception Status Benefits: Zejula (niraparib), Adlyxine (lixisenatide), Entyvio (vedolizumab). Criteria Updates: Entyvio (vedolizumab), Lenvima (lenvatinib), Nexavar (sorafenib). New Benefits: Ceftazidime. New Diabetic Products
February Bulletin Vol 22-02 (PDF)
New Exception Status Benefits Ajovy (fremanezumab); Monoferric (ferric derisomaltose); Opsumit (macitentan); Riabni (rituximab). Criteria Updates Androgel and generic brands (testosterone); Testim (testosterone); Zofran and generic brands (ondansetron); Cosentyx (secukinumab)
February Bulletin Vol 22-01 (PDF)
New Exception Status Benefit Nyvepria (pegfilgrastim): Criteria Updates, Mozobil (plerixafor), Erleada (apalutamide), Xtandi (enzalutamide), Zytiga and generic brands (abiraterone), Riximyo (rituximab), Erelzi (etanercept)